Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Meet the New Chief: McCloskey Takes Helm at John Theurer Cancer Center’s Leukemia Division

October 15th 2020

As James K. McCloskey II, MD, begins the next chapter of his career as chief of the Division of Leukemia at John Theurer Cancer Center at Hackensack University Medical Center.

FDA Approves Pembrolizumab for Relapsed/Refractory Classical Hodgkin Lymphoma

October 15th 2020

The FDA has approved an expanded label for pembrolizumab for use as a monotherapy in the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma and pediatric patients with refractory classical Hodgkin lymphoma, or classical Hodgkin lymphoma that has relapsed after 2 or more lines of therapy.

Copanlisib/Rituximab Prolongs PFS in Relapsed Indolent Non-Hodgkin Lymphoma

October 15th 2020

Copanlisib in combination with rituximab prolonged progression-free survival in patients with non-Hodgkin lymphoma who relapsed following 1 or more previous lines of rituximab-based therapy.

Dr. Silbermann on the Role of Disease Biology in Multiple Myeloma

October 13th 2020

Rebecca Silbermann, MD, MMS, discusses the role of disease biology in multiple myeloma.

Mogamulizumab Significantly Boosts Outcomes in CTCL With Blood Involvement

October 13th 2020

Higher levels of blood tumor involvement were linked with more favorable outcomes in patients who received treatment with mogamulizumab compared with vorinostat in patients with 2 types of cutaneous T-cell lymphoma.

CD38-Directed Regimens Lead the Pack in Relapsed/Refractory Myeloma Treatment

October 12th 2020

Rebecca Silbermann, MD, MMS, discusses combinations featuring the monoclonal antibodies daratumumab or isatuximab-irfc and how they have made notable differences in outcomes for patients with relapsed/refractory multiple myeloma.

Dr. Martin on the Need for Head-to-Head Comparisons of BTK Inhibitors in MCL

October 12th 2020

Peter Martin, MD, discusses the need for head-to-head comparison of BTK inhibitors in mantle cell lymphoma.

Dr. Hill on Future Research With CAR T-Cell Therapy in B-Cell Lymphomas

October 12th 2020

Brian T. Hill, MD, PhD, discusses future research with CAR T-cell therapy in hematologic malignancies.

Quadruplet Regimens Seek to Raise the Bar in Frontline Multiple Myeloma

October 12th 2020

Derek Galligan, MD, discusses the role of 3-drug combinations and ongoing research efforts that are focused on evaluating the use of quadruplet regimens earlier on in the treatment journey.

Dr. Hill on Managing CRS in Patients Treated With CAR T-Cell Therapy

October 9th 2020

Brian T. Hill, MD, PhD, discusses the management of cytokine release syndrome in patients with hematologic malignancies who are treated with CAR T-cell therapy.

Targeted Therapy Options Transform AML Paradigm

October 9th 2020

An increased understanding of the biologic intricacies of acute myeloid leukemia has led to the identification of more than 100 driver mutations associated with the disease, opening the door for targeted therapies with clinically meaningful outcomes for patients who are not candidates for intensive chemo-therapy regimens.

Current and Emerging Treatments in Follicular Lymphoma

October 9th 2020

Although the majority of patients with follicular lymphoma have a life expectancy similar to that of the general population, predicting which patients will relapse and finding therapies that provide durable responses in the relapsed or refractory setting remains an ongoing challenge.

Dr. Deol on the Curative Potential of CAR T-Cell Therapy in ALL

October 8th 2020

Abhinav Deol, MD, discusses the role of CAR T-cell therapy in pediatric patients with acute lymphoblastic leukemia.

NEDD8 Emerges as a Novel Target in Hematologic Malignancies

October 8th 2020

Investigators are developing a new way to target a key oncogenic mechanism that may prove to be an effective anticancer strategy, particularly against hematologic malignancies.

Eprenetapopt May Develop Into New Option for TP53-Mutant MDS

October 7th 2020

The addition of the experimental small molecule eprenetapopt to a standard treatment for myelodysplastic syndromes is showing promise in patients with TP53 mutations.

Dr. Deol on the Utility of Tisagenlecleucel in ALL

October 7th 2020

Abhinav Deol, MD, discusses the approval of the CAR T-cell therapy tisagenlecleucel for pediatric patients with acute lymphoblastic leukemia.

Dr. Gajra on Adverse Effects Associated With CAR T-Cell Therapy in Hematologic Malignancies

October 6th 2020

Ajeet Gajra, MD, FACP, discusses adverse effects associated with CAR T-cell therapy in hematologic malignancies.

Omidubicel Meets All Secondary End Points of Phase 3 Trial in Hematologic Malignancies

October 6th 2020

The investigational advanced cell therapy omidubicel resulted in rapid platelet engraftment and reduced the number of infections and hospitalizations in patients with high-risk hematologic malignancies, meeting all 3 secondary end points of a phase 3 trial.

Dr. Vesole on the Advantages of CAR T-Cell Therapy in Multiple Myeloma

October 5th 2020

David H. Vesole, MD, PhD, discusses the advantages of CAR T-cell therapy in multiple myeloma.

FDA Grants Breakthrough Therapy Designation to IMGN632 in Relapsed/Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm

October 5th 2020

The FDA has granted a breakthrough therapy designation to IMGN632 for the treatment of patients with relapsed or refractory blastic plasmacytoid dendritic cell neoplasm.